Martin Rudwaleit

Summary

Publications

  1. ncbi Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
    Martin Rudwaleit
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin Hospital, Hindenburgdamm 30, 12200 Berlin, Germany
    Arthritis Res Ther 12:R117. 2010
  2. ncbi Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
    Martin Rudwaleit
    Charite University Medicine Berlin, Benjamin Franklin Campus, Medical Department I, Rheumatology, Hindenburgdamm 30, 12203 Berlin, Germany
    Arthritis Res Ther 12:R43. 2010
  3. ncbi The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic
    Denis Poddubnyy
    Rheumatology, Medical Department I, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Hindenburgdamm 30, Berlin 12203, Germany
    Ann Rheum Dis 71:1998-2001. 2012
  4. ncbi Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care
    Denis Poddubnyy
    Department of Rheumatology, Charite Campus Benjamin Franklin, Berlin, Germany
    J Rheumatol 38:2452-60. 2011
  5. ncbi Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis
    Martin Rudwaleit
    Charite University Medicine Berlin, Campus Benjamin Franklin Hospital, Medical Department I, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
    J Rheumatol 36:801-8. 2009
  6. ncbi Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion
    Martin Rudwaleit
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin Hospital, Berlin, Germany
    Rheumatology (Oxford) 48:551-7. 2009
  7. ncbi Diagnosing early ankylosing spondylitis
    In Ho Song
    Rheumatology, Department of Medicine, Charité Medical University Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Curr Rheumatol Rep 9:367-74. 2007
  8. ncbi Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Arthritis Res Ther 10:R125. 2008
  9. ncbi A case of axial undifferentiated spondyloarthritis diagnosis and management
    Martin Rudwaleit
    Rheumatology, Department of Medicine I, Charite Universitatsmedizin, Berlin, Germany
    Nat Clin Pract Rheumatol 3:298-303. 2007
  10. ncbi Early spondyloarthritis
    Denis Poddubnyy
    Rheumatology, Medical Department I, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Hindenburgdamm 30, Berlin 12203, Germany
    Rheum Dis Clin North Am 38:387-403. 2012

Collaborators

Detail Information

Publications16

  1. ncbi Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
    Martin Rudwaleit
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin Hospital, Hindenburgdamm 30, 12200 Berlin, Germany
    Arthritis Res Ther 12:R117. 2010
    ..Our objective was to evaluate the effectiveness and safety of adalimumab, 40 mg every other week, for patients with AS or PsA and prior treatment with infliximab (IFX) and/or etanercept (ETN)...
  2. ncbi Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
    Martin Rudwaleit
    Charite University Medicine Berlin, Benjamin Franklin Campus, Medical Department I, Rheumatology, Hindenburgdamm 30, 12203 Berlin, Germany
    Arthritis Res Ther 12:R43. 2010
    ..The purpose of this study was to investigate the effectiveness of adalimumab in enthesitis and peripheral arthritis in patients with ankylosing spondylitis (AS)...
  3. ncbi The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic
    Denis Poddubnyy
    Rheumatology, Medical Department I, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Hindenburgdamm 30, Berlin 12203, Germany
    Ann Rheum Dis 71:1998-2001. 2012
    ....
  4. ncbi Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care
    Denis Poddubnyy
    Department of Rheumatology, Charite Campus Benjamin Franklin, Berlin, Germany
    J Rheumatol 38:2452-60. 2011
    ..To evaluate 2 referral strategies for axial spondyloarthritis (SpA) in patients with chronic low back pain at the primary care level...
  5. ncbi Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis
    Martin Rudwaleit
    Charite University Medicine Berlin, Campus Benjamin Franklin Hospital, Medical Department I, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
    J Rheumatol 36:801-8. 2009
    ..We evaluated the effectiveness and safety of adalimumab in a large cohort of patients with active ankylosing spondylitis (AS) and identified clinical predictors of good clinical response...
  6. ncbi Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion
    Martin Rudwaleit
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin Hospital, Berlin, Germany
    Rheumatology (Oxford) 48:551-7. 2009
    ..To evaluate the effectiveness and safety of adalimumab in treating patients with AS and advanced structural damage...
  7. ncbi Diagnosing early ankylosing spondylitis
    In Ho Song
    Rheumatology, Department of Medicine, Charité Medical University Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Curr Rheumatol Rep 9:367-74. 2007
    ..Finally, referral strategies for patients seen by primary care physicians seem to work well and are currently under further valuation...
  8. ncbi Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Arthritis Res Ther 10:R125. 2008
    ..Therefore, we analysed parameters of cartilage degradation, neoangiogenesis, and new bone formation in different cohorts of patients with axial spondyloarthritis with and without treatment with TNF-alpha blocker agents...
  9. ncbi A case of axial undifferentiated spondyloarthritis diagnosis and management
    Martin Rudwaleit
    Rheumatology, Department of Medicine I, Charite Universitatsmedizin, Berlin, Germany
    Nat Clin Pract Rheumatol 3:298-303. 2007
    ..A 32-year-old white man presented with features of inflammatory back pain, including awakening at night and morning stiffness. He had acute back pain 4 years earlier as a result of a herniated lumbar disc...
  10. ncbi Early spondyloarthritis
    Denis Poddubnyy
    Rheumatology, Medical Department I, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Hindenburgdamm 30, Berlin 12203, Germany
    Rheum Dis Clin North Am 38:387-403. 2012
    ..This article discusses the current concept of the disease, typical manifestations, advances in diagnosis, and current treatment recommendations...
  11. ncbi Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort
    Denis Poddubnyy
    Med Department I, Rheumatology, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Ann Rheum Dis 71:1616-22. 2012
    ..To investigate the influence of non-steroidal anti-inflammatory drugs (NSAIDs) intake on radiographic spinal progression over 2 years in patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (SpA)...
  12. ncbi Limited diagnostic value of unilateral sacroiliitis in scintigraphy in assessing axial spondyloarthritis
    In Ho Song
    Charité Medical University, Campus Benjamin Franklin, Medical Clinic I, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
    J Rheumatol 37:1200-2. 2010
    ..To assess the diagnostic value for axial spondyloarthritis (SpA) of unilateral sacroiliitis in scintigraphy in daily clinical practice...
  13. ncbi Adalimumab improves sleep and sleep quality in patients with active ankylosing spondylitis
    Martin Rudwaleit
    Charite University, Benjamin Franklin Campus, Berlin, Germany
    J Rheumatol 38:79-86. 2011
    ..This subanalysis of the RHAPSODY study (Review of Safety and Effectiveness with Adalimumab in Patients with Active Ankylosing Spondylitis) was conducted to evaluate the effect of adalimumab on sleep in patients with active AS...
  14. ncbi New approaches to diagnosis and classification of axial and peripheral spondyloarthritis
    Martin Rudwaleit
    Charite University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany
    Curr Opin Rheumatol 22:375-80. 2010
    ..The diagnostic delay in AS of several years is mainly attributable to the late appearance of definite sacroiliitis on radiographs. Efforts have been made in recent years to improve and standardize making an early diagnosis...
  15. ncbi Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis
    Henning Christian Brandt
    Rheumatology, Department of Medicine I, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 66:1479-84. 2007
    ..Referral parameters that are easy for doctors in primary care to apply to patients presenting with possible AS could contribute to earlier diagnosis...
  16. ncbi Adalimumab for the treatment of ankylosing spondylitis
    Joachim Sieper
    Campus Benjamin Franklin, Rheumatology, Medical Department I, Charite, Hindenburgdamm 30, 12200 Berlin, Germany
    Expert Opin Pharmacother 8:831-8. 2007
    ..In open and placebo-controlled trials, the drug was shown to be safe and effective in ankylosing spondylitis patients. Long-term treatment data of up to 2 years are now available, confirming efficacy and acceptable safety...